PLOS: DNA Science

JUNE 1, 2023

The newest FDA-approved gene therapy treats the severe, skin-peeling condition dystrophic epidermolysis bullosa (DEB). The gene treatment has been a long time coming, but it differs from the handful of other approved gene therapies: it isn’t a one-and-done. DEB has been a candidate for a gene therapy since 2002.

FDA Approval 52

FDA Approval Therapies FDA Disease 52

The Pharma Data

MARCH 25, 2021

With more than six years of patient experience, a positive benefit-risk profile, strong clinical data and robust real-world data, the totality of evidence solidifies the role of IBRANCE plus endocrine therapy as a treatment for patients with HR+, HER2- metastatic breast cancer.”. The analysis also showed the two-year OS rate was 78.3%

Therapies 52

Therapies Clinical Trials Trials Treatment 52

The Pharma Data

DECEMBER 3, 2020

The TAK-620-303 (SOLSTICE) trial (NCT02931539) is a multicenter, randomized, open-label, active-controlled trial comparing eight weeks of treatment with either maribavir or investigator assigned treatment (IAT) in transplant recipients with CMV infection refractory or resistant to existing antiviral treatments (i.e.,

Treatment 52

Treatment Pharmaceutical Companies Therapies Virus 52

The Pharma Data

AUGUST 27, 2020

. MSD’s Keytruda (pembrolizumab) in combination with Pfizer’s Inlyta (axitinib) has been turned down by NICE as first-line treatment for patients with advanced renal cell carcinoma (RCC). Axitinib and pembrolizumab improves survival significantly and has an important role to play in the treatment of kidney cancer.

Clinical Trials 52

Clinical Trials Nurses Trials Treatment 52

The Pharma Data

NOVEMBER 20, 2020

(NASDAQ: REGN) today announced that the antibody cocktail casirivimab and imdevimab administered together (formerly known as REGN-COV2 or REGEN-COV2), a therapy currently being investigated for use in COVID-19 , has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA). Schleifer, M.D.,

Therapies 52

Therapies FDA Clinical Trials Hospitals 52

The Pharma Data

JANUARY 26, 2021

percent) in patients taking therapy and 36 events (7.0 Bamlanivimab and etesevimab together also demonstrated statistically significant improvements on all key secondary endpoints, providing strong evidence that the therapy reduced viral load and accelerated symptom resolution. INDIANAPOLIS, Jan. have reached record highs. .

Hospitals 52

Hospitals Treatment Trials Long-Term Care Facilities 52

The Pharma Data

AUGUST 11, 2020

.–( BUSINESS WIRE )– Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 CheckMate -577 trial evaluating Opdivo (nivolumab) as an adjuvant therapy for patients with resected esophageal or gastroesophageal junction (GEJ) cancer met its primary endpoint of disease-free survival (DFS) at a pre-specified interim analysis.

Therapies 52

Therapies Trials Disease Treatment 52

The Pharma Data

NOVEMBER 18, 2020

18, 2020 /PRNewswire/ — Tampa General Hospital provided the first monoclonal antibody treatment to a COVID-19 positive patient today. This single dose infusion-based treatment is provided on an outpatient basis and marks a dramatic shift in COVID-19 care. Currently receiving immunosuppressive treatment.

Hospitals 40

Hospitals Treatment Virus Nurses 40

The Pharma Data

APRIL 28, 2023

Teva and MedinCell Announce FDA Approval of UZEDY™ (risperidone) Extended-Release Injectable Suspension, a Long-Acting Subcutaneous Atypical Antipsychotic Injection, for the Treatment of Schizophrenia in Adults Teva Pharmaceuticals, a U.S. We are committed to supporting patients through innovative therapy options.

FDA Approval 40

FDA Approval Treatment FDA Clinical Trials 40

The Pharma Data

AUGUST 11, 2020

We look forward to engaging health authorities worldwide with the goal of bringing this immunotherapy-based treatment option to patients as soon as possible.”. All patients continued treatment for two years or until disease progression, unacceptable toxicity or withdrawal of consent. Waxman, M.D., About Esophageal Cancer.

Treatment 52

Treatment Trials Therapies Clinical Trials 52

The Pharma Data

APRIL 8, 2021

today announced that new data for its approved and investigational medicines for the treatment of neurological disorders will be presented at the 73rd American Academy of Neurology (AAN) Annual Meeting being held virtually April 17-22, 2021. Following U.S. Roche’s Chief Medical Officer and Head of Global Product Development.

Clinical Trials 52

Clinical Trials Trials Disease Therapies 52

The Pharma Data

OCTOBER 25, 2020

Food and Drug Administration (“FDA”) for the treatment of agitation associated with delirium. Treatment choices are limited, and commonly used off-label therapies are not always effective or may result in prolonged, deep sedation. NEW HAVEN, Conn., 26, 2020 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (“BTI”

Treatment 40

Treatment Trials FDA Hospitals 40

The Pharma Data

NOVEMBER 6, 2020

Our findings underscore the importance of early referral of suspected cases for expert diagnosis and treatment.” HSS was the first in New York State to receive Magnet Recognition for Excellence in Nursing Service from the American Nurses Credentialing Center four consecutive times. ” About HSS. www.hss.edu.

Nurses 52

Nurses Hospitals Disease Therapies 52

The Pharma Data

JANUARY 27, 2021

The report entitled “Pre-Exposure Prophylaxis for COVID-19 in Pregnant Women” was written by nurse practitioner Melissa Fesler and internist Raphael Stricker from the Alan E. This antimicrobial agent was originally promoted for treatment of severe SARS-CoV-2 infection using high daily doses in combination with other medications.

Vaccine 52

Vaccine Nurses International Treatment 52

The Pharma Data

NOVEMBER 4, 2020

New data will also be presented that show the safety and efficacy of ULTOMIRIS when used concomitantly with immunosuppressive therapy (IST) in patients with PNH. The prognosis for patients with aHUS can be poor in many cases, so a timely and accurate diagnosis—in addition to treatment—is critical to improving patient outcomes.

Doctors 52

Doctors Vaccine Nurses Treatment 52

The Pharma Data

JUNE 18, 2021

“The CLL14 trial results observed after four years of follow-up with treatment of venetoclax plus obinutuzumab show that these patients can experience long-lasting responses without disease progression, years after stopping treatment,” said Mohamed Zaki , M.D., vice president and head, global oncology development, AbbVie.

Treatment 40

Treatment Trials Therapies Clinical Trials 40

The Pharma Data

NOVEMBER 19, 2020

A study out of Rutgers University found that healthcare staffers, especially nurses, have a higher prevalence of COVID-19 than non-healthcare workers. Of the 40 healthcare workers who tested positive of the study group, 25 were nurses. Here’s a look at some of the more interesting ones. Healthcare Workers Most at Risk for COVID-19.

Research 52

Research Nurses Disease Immune Response 52

The Pharma Data

JANUARY 26, 2021

Data published last week showed that bamlanivimab significantly reduced COVID-19 risk for nursing home residents in a Phase III trial. . Eli Lilly’s bamlanivimab, a neutralizing antibody initially developed by AbCellera, was approved for emergency use authorization in November by the U.S.

Virus 52

Virus Trials Nurses Research Laboratories 52

The Pharma Data

NOVEMBER 10, 2020

SAMI is a renal replacement therapy (RRT) machine manufactured and commercialized by Spectral’s wholly-owned subsidiary, Dialco Medical Inc. ( “Dialco” ). The paper describes the first month of using SAMI as part of UMMC’s PIRRT (Prolonged Intermittent Renal Replacement Therapy) program throughout April 2020.

Therapies 52

Therapies FDA FDA Approval Nurses 52

The Pharma Data

JUNE 18, 2021

. “We are encouraged by these promising results, which indicate ibrutinib and venetoclax combined has the potential to serve as an important chemotherapy-free, fixed-duration treatment option for people living with CLL,” said Dr. Paolo Ghia , M.D., 95% irrespective of subsequent randomized treatment ( Wierda, ASH 2020 ).

Treatment 40

Treatment FDA Therapies FDA Approval 40

KIF1A

APRIL 27, 2024

Where’s the best therapy? We sold our house, I gave up my career as a nurse, and we moved to Calgary. We’ve raised over $50,000 as a family to fund research for treatments that are currently in the works right now. “I immediately started researching where in Canada has the best resources for Emma. Amanda says. “We

Doctors 52

Doctors Nurses Disease Therapies 52

Codon

JANUARY 21, 2024

yellow fever, malaria, and dengue), evaluating new drugs or treatments, and studying pathogenesis, the process by which a disease develops. Scientists studied black men infected with syphilis for several decades while withholding known treatments. You can do a challenge trial with deadly diseases, but you need a “rescue therapy.”

Vaccine 124

Vaccine Trials Disease Treatment 124

Altus Drug Development

MAY 31, 2022

Value-added medicines offer the medical world the opportunity to increase the quality of treatments as well as expand access to healthcare for more people. Value-added medicines are drug products and treatments created using known molecules through a process known as drug repositioning. What is a value-added medicine?

Treatment 52

Treatment Pharmaceuticals Production Doctors 52

The Pharma Data

FEBRUARY 8, 2021

IBRANCE is indicated for the treatment of adult patients with HR+, HER2- advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine based therapy in postmenopausal women or in men; or with fulvestrant in patients with disease progression following endocrine therapy. 2,3 In the U.S.,

Clinical Trials 52

Clinical Trials Treatment Therapies Production 52

The Pharma Data

JULY 23, 2021

Food and Drug Administration (FDA) approved DALVANCE® (dalbavancin) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in pediatric patients from birth. “This pediatric approval for DALVANCE as a single-dose provides a meaningful contribution to the treatment of children and infants with ABSSSI.”

FDA Approval 52

FDA Approval FDA Clinical Trials Trials 52

The Pharma Data

DECEMBER 17, 2020

These follow-on data provided the first definitive prospective evidence demonstrating anti-viral activity for a treatment regimen now available for COVID-19, and also further documented the ability of this treatment to decrease the need for further medical attention,” said George D. who require oxygen therapy due to COVID-19, OR.

Hospitals 52

Hospitals Production Clinical Trials Virus 52

The Pharma Data

JUNE 18, 2021

The safety profile of I+V was generally consistent with the safety profile of the single agents and tolerability profiles were consistent with CLL treatment in the enrolled patient population. Three months after the completion of treatment uMRD was observed in 51.9% Time to subsequent therapy was longer for I+V (HR 0.143, 95% CI 0.05-0.41).

Treatment 52

Treatment Therapies FDA FDA Approval 52

The Pharma Data

DECEMBER 29, 2020

First antibody therapy to demonstrate anti-viral effect in patients hospitalized with COVID-19. The benefit was driven by results starting one week post-treatment, when the risk of death or receiving mechanical ventilation was reduced by approximately half with antibody cocktail treatment, based on a post-hoc analysis.

Hospitals 52

Hospitals Trials Clinical Trials Production 52

The Pharma Data

JANUARY 12, 2021

Patients, caregivers and healthcare providers can find sites with COVID-19 antibody treatments through these links to the HHS or National Infusion Center Association locator tools. . Regeneron is responsible for development and distribution of the treatment in the U.S. , who require oxygen therapy due to COVID-19, OR.

Government 52

Government Hospitals Virus Clinical Trials 52

The Pharma Data

AUGUST 6, 2020

In 2016, data became increasingly available on the safety profile of fluoroquinolone antibiotics, specifically around inappropriate use as a first-line therapy which raised concern of potential harm to patients. The history of fluoroquinolones. Medscape and the FDA collaborative research. This target audience wrote 7.3

FDA 52

FDA Nurses Hospitals Therapies 52

The Pharma Data

JANUARY 24, 2021

National Institute of Allergy and Infectious Diseases (NIAID), of bamlanivimab (LY-CoV555) decreased the risk of COVID-19 among residents and staff of long-term care facilities, i.e., nursing homes. The trial will evaluate a single dose of firibastat 1000mg compared to placebo, on top of the patients’ current therapy.

Long-Term Care Facilities 52

Long-Term Care Facilities Trials Virus Clinical Trials 52

The Pharma Data

DECEMBER 1, 2020

13 to 17 and attracted participants from around the world, including cardiovascular specialists, surgeons, and nurses as well as other health care professionals. AHA: Ablation Better Than Meds for Initial A-Fib Treatment. AHA: Black Patients Less Likely to Receive Indicated BP Treatment Intensification. ” Press Release.

Hospitals 52

Hospitals Disease Treatment Therapies 52

The Pharma Data

NOVEMBER 20, 2020

” Debra Moser, a professor and assistant dean at the University of Kentucky College of Nursing in Lexington, said the new study shows that health care professionals need to do a better job of managing depression. Medications, talk therapy and exercise can help, Moser and Celano said. That is “critical.

Disease 52

Disease Nurses Research Hospitals 52

The Pharma Data

APRIL 28, 2021

The positive CHMP opinion is a scientific recommendation for marketing authorization to the European Commission (EC), which is expected to deliver its final decision on VENCLYXTO combination therapy for use in AML in the first half of 2021. .” NORTH CHICAGO, Ill. ” AML is the most common acute leukemia in the world.

Clinical Trials 40

Clinical Trials Trials Treatment Therapies 40

The Pharma Data

DECEMBER 3, 2020

An initial analysis of data from 17/22 patients who completed one of these assessments showed substantially decreased neurocognitive abilities compared to children of the same age level despite the use of multiple anti-epileptic therapies. In addition, a gap in adaptive functioning was noted using the Vineland Adaptive Behavior Scales.

Clinical Trials 52

Clinical Trials Protein Expression Pharmacokinetics Trials 52

The Pharma Data

JUNE 18, 2021

May 25, 2021 /PRNewswire/ — AbbVie (NYSE: ABBV) announced today that the European Commission (EC) has approved VENCLYXTO ® (venetoclax) in combination with a hypomethylating agent, azacitidine or decitabine, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy.

Clinical Trials 40

Clinical Trials Treatment Trials Therapies 40

The Pharma Data

NOVEMBER 21, 2020

21, 2020 /PRNewswire/ — First treatment of any kind to have prospectively confirmed and statistically significant anti-viral activity against SARS-CoV-2. TARRYTOWN, N.Y. , Authorized for recently diagnosed, mild to moderate COVID-19 in high-risk patients. government allocation program. Food and Drug Administration (FDA).

FDA 40

FDA Clinical Trials Hospitals Production 40